Market Place
Sourcing Support
Ferring Pharma, Gallup Launch Global Fertility Attitudes Study
16 Apr 2026 //
BUSINESSWIRE
BCAN Taps Ferring, Astellas/Pfizer for 2026 Initiatives
09 Apr 2026 //
GLOBENEWSWIRE
Ferring Terminates Fertility Trials After `Portfolio Assessment`
02 Apr 2026 //
FIERCE BIOTECH
Ferring Upgrades Adstiladrin to NCCN Category 2A for NMIBC
19 Mar 2026 //
BUSSINESSWIRE
Ferring, Theralase Partner For Bladder Cancer Combo Therapy
12 Jan 2026 //
PHARMIWEB
SUO And Ferring Pharma Unveil (NMIBC) Fellows Research Grant
02 Dec 2025 //
BUSINESSWIRE
2 in 5 Workers Quit Over Fertility Treatments
26 Nov 2025 //
BUSINESSWIRE
Ferring Pharmaceuticals To Explore Strategic Options For Rebyota®
29 Oct 2025 //
BUSINESSWIRE
Ferring Will Lay Off 64 Employees In New Jersey
28 Oct 2025 //
BIOSPACE
Ferring Pharma Unveils New Analyses Of Follitropin Delta Data
27 Oct 2025 //
BUSINESS WIRE
Ferring Unveils Rebyota Data Analysis at Acg 2025
27 Oct 2025 //
BUSINESS WIRE
Ferring Highlights REBYOTA® Real-World Data Showing Patient
20 Oct 2025 //
BUSINESSWIRE
Ferring Expands Real-World Evidence For ADSTILADRIN® In Urology
16 Oct 2025 //
BUSINESSWIRE
Ferring`s Shift To New Business Model Claims 500 Jobs Worldwide
09 Oct 2025 //
BIOSPACE
After Revealing Reorganization, Ferring Says It Will Lay Off 500
08 Oct 2025 //
FIERCE PHARMA
Ferring Presents Phase 3b Data for REBYOTA at DDW
05 May 2025 //
BUSINESSWIRE
U.S. FDA Approves Second ADSTILADRIN® Drug Manufacturing Facility
24 Apr 2025 //
BUSINESSWIRE
Ferring Highlights Commitment to C. Diff Infection Community
27 Jan 2025 //
BUSINESSWIRE
Genpact Extends Partnership With Ferring To Enhance Operations
22 Nov 2024 //
EXPRESSPHARMA
Ferring Presents REBYOTA® Data Analyses at ACG 2024
28 Oct 2024 //
BUSINESSWIRE
Ferring Pharmaceuticals Commits To Advancing Fertility Care At ASRM
18 Oct 2024 //
BUSINESSWIRE
Ferring Presents Rebyota Outcomes Data At IDWeek 2024
16 Oct 2024 //
BUSINESSWIRE
Ferring`s Treat-To-Target Approach In Colitis found effective
30 Sep 2024 //
BUSINESSWIRE
Ferring Presents SI-6603 Phase 3 Data At NASS 2024
25 Sep 2024 //
BUSINESSWIRE
Ferring To Present SI-6603 Data For Disc Herniation At NASS 2024
09 Sep 2024 //
BUSINESSWIRE
Ferring Presents SI-6603 Phase 3 Data For Lumbar Disc Herniation At ASPN
15 Jul 2024 //
BUSINESSWIRE
Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, for Herniation
24 Jun 2024 //
BUSINESSWIRE
First Real-World REBYOTA Data Presented At DDW 2024
20 May 2024 //
BUSINESSWIRE
Ferring Presents Ph 3 Data for Investigational Treatment at ASIPP 2024
08 Apr 2024 //
BUSINESSWIRE
Phase 4 Study Evaluating Use of ADSTILADRIN in Real-World Setting
24 Jan 2024 //
BUSINESSWIRE
Ferring Announces Full Availability of ADSTILADRIN in the U.S.
16 Jan 2024 //
BUSINESSWIRE
Ferring lays off 134 staffers in the US
12 Dec 2023 //
FIERCE PHARMA
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration
11 Dec 2023 //
BUSINESSWIRE
Ferring Pharmaceuticals lays off 134 employees between NJ and MN locations
11 Dec 2023 //
ENDPTS
New Data Show Durable Response Following Treatment with ADSTILADRIN
29 Nov 2023 //
BUSINESSWIRE
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA
03 Oct 2023 //
BUSINESSWIRE
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA
21 Sep 2023 //
BUSINESSWIRE
Largest Safety Analysis From Five Prospective Trials for REBYOTA Published
11 Jul 2023 //
BUSINESSWIRE
Ferring appoints new Executive Chairman among key changes to Board of Directors
22 Jun 2023 //
BUSINESSWIRE
Ferring successfully increases its second Swiss Franc Bond offering by CHF 80 M
16 Jun 2023 //
BUSINESSWIRE
Ferring Announces Positive Topline Phase 3 Results for SI-6603
26 May 2023 //
BUSINESSWIRE
Four Analyses of Data for REBYOTA™ the First FDA-Approved Microbiome
08 May 2023 //
BUSINESSWIRE
CORONA, Ferring partner to commercialise maternal health, urology products India
04 May 2023 //
EXPRESS PHARMA
Ferring & BioInnovation enter new strategic collaboration women’s health
18 Apr 2023 //
BUSINESSWIRE
Ferring to Present Analyses of Data for REBYOTA™ the First FDA-Approved
18 Apr 2023 //
BUSINESSWIRE
Ferring`s research site closure signals shift from internal R&D
11 Apr 2023 //
FIERCE BIOTECH
Ferring shuts down U.S. research institute, cutting 89 staffers
29 Mar 2023 //
FIERCE BIOTECH
Ferring Announces Abstract of the Study of Rekovelle
13 Mar 2023 //
BUSINESSWIRE
Ferring Announces Availability of REBYOTA – the First Microbiome-Based Treatment
14 Feb 2023 //
BUSINESSWIRE
U.S. FDA Approves Ferring Pharma`s First Gene Therapy For Bladder Cancer
17 Dec 2022 //
PRESS RELEASE
FDA Approves First Fecal Microbiota Product Rebyota
01 Dec 2022 //
FDA
Pivotal Phase 3 Efficacy & Safety Data for Ferring’s RBX2660 Published in Drugs
07 Nov 2022 //
BUSINESSWIRE
Ferring halts shipments of fertility med Menopur
28 Oct 2022 //
FIERCEPHARMA
Ferring Presents Seven New Analyses at ACG 2022 for RBX2660
24 Oct 2022 //
BUSINESSWIRE
Ferring Pharmaceuticals Announces the Launch of FertilityWise
21 Oct 2022 //
PRNEWSWIRE
Ferring Presents Analyses of Quality of Life & Efficacy Data for RBX2660
20 Oct 2022 //
BUSINESSWIRE
Ferring to Present Data Highlighting Future Assisted Reproductive Technology
19 Oct 2022 //
PRNEWSWIRE
Ferring & Blackstone Life Sciences restructure novel gene therapy collaboration
18 Oct 2022 //
PRESS RELEASE
Ferring to Present Analyses for RBX2660 in Patients at ACG 2022
11 Oct 2022 //
BUSINESSWIRE
Ferring to Present Analyses for Microbiota-Based Biotherapeutic RBX2660
06 Oct 2022 //
BUSINESSWIRE
